Premium
Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration
Author(s) -
Hornsey V. S.,
Young D. A.,
Docherty A.,
Hughes W.,
Prowse C. V.
Publication year - 2004
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/j.0958-7578.2004.00528.x
Subject(s) - cryoprecipitate , fibrinogen , methylene blue , chemistry , chromatography , medicine , andrology , biochemistry , photocatalysis , catalysis
summary. When cryoprecipitate is prepared from plasma which has been treated with methylene blue plus light (MB) for the purpose of virus inactivation, clottable fibrinogen content is 40% lower compared with units prepared from untreated plasma. Initial studies showed that when frozen MB plasma units were removed to +2 to +6 °C for 4 h and then returned to −40 °C prior to cryoprecipitation, fibrinogen recoveries increased from 24 to 42%. Although fibrinogen yield improved when plasma units were stored at +2 to +6 °C for varying lengths of time, FVIII levels decreased with increasing time. Conditioning for 8 h was studied in more detail. Groups of two plasma units were mixed together, divided into two equal units, frozen/thawed and treated with MB. One of each pair was stored continually at −40 °C, whereas the other was removed to +2 to +6 °C for 8 h. Samples were assayed for fibrinogen, FVIII, VWF:Ristocetin cofactor activity (RCo), VWF:Ag and VWF:Collagen binding (CB). The cryoprecipitate fibrinogen content increased to a mean of 207 mg unit −1 . VWF:Ag, VWF:RCo and VWF:CB recoveries also increased. FVIII recovery decreased from 50 to 45% (mean 124 iu unit −1 ). Conditioning has been validated for routine production of cryoprecipitate from imported plasma.